Evidence map›Paper›PMID 40113956›Full record

ArticleScientific reports2025

A population‑based propensity score matching analysis of neoadjuvant compared to adjuvant chemotherapy in luminal breast cancer.

Chenhui Zheng, Danni Zheng, Yuzhu Zhang, Renzhi Lin, Zhibao Zheng

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chenhui ZhengDepartment of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Danni ZhengDepartment of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Yuzhu ZhangDepartment of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Renzhi LinDepartment of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
Zhibao ZhengDepartment of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China. zhengzb@tzc.edu.cn.

Funding

The study has funded by the Program of Taizhou Science and Technology Bureau,Zhejiang Province 23ywa19
6 · The paper itself

Abstract

This study evaluated the long-term prognosis of patients with luminal (HR+/HER2-) breast cancer who underwent either neoadjuvant or adjuvant chemotherapy. Between January 2014 and December 2018, 1065 h+/HER2- breast cancer patients were retrospectively analyzed. Each patient receiving neoadjuvant chemotherapy was matched with two patients receiving adjuvant chemotherapy using a 1:2 propensity score matching (PSM) approach. After matching, 47 neoadjuvant chemotherapy patients and 89 adjuvant chemotherapy patients were included. The clinical and pathological characteristics of both groups were compared, and risk factors for postoperative events were assessed alongside a survival analysis. Following propensity score matching, the characteristics of the two groups were well balanced. The study identified lower progesterone receptor (PR) expression, histological grade III, and lymph node metastasis as independent risk factors for recurrence-free survival (RFS). No significant difference in RFS was observed between neoadjuvant and adjuvant chemotherapy. It is recommended that patients with HR+/HER2- breast cancer who exhibit a poor response to neoadjuvant chemotherapy should undergo early surgery, with personalized treatment decisions based on postoperative pathological findings.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyAdultAgedChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPrognosisPropensity ScoreReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerHR+/HER2−Neoadjuvant chemotherapyPropensity score matchingRecurrence-free survival

Identifiers

PMID40113956
PMCPMC11926370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.